骨硬化蛋白抗体的临床研究进展

doi:10.13701/j.cnki.kqyxyj.2019.12.004

口腔医学研究 ›› 2019, Vol. 35 ›› Issue (12): 1119-1121.DOI: 10.13701/j.cnki.kqyxyj.2019.12.004

骨硬化蛋白抗体的临床研究进展

梁婷婷, 郭吕华^*

广州医科大学附属口腔医院广州口腔病研究所口腔医学重点实验室广东广州 510140

收稿日期:2019-09-28 出版日期:2019-12-28 发布日期:2019-12-23
通讯作者: 郭吕华,E-mail:562210919@qq.com
作者简介:梁婷婷(1993~ ),女,广东江门人,硕士,研究方向:3D打印技术对成骨的研究与应用。
基金资助:
广东省科技计划项目(编号:2017A050501041)

Research Progress on Sclerostin Antibody

LIANG Tingting, GUO Lvhua^*

Key Laboratory of Oral Medicine, Guangzhou Institute of Oral Disease, Stomatology Hospital of Guangzhou Medical University, Guangzhou 510140, China.

Received:2019-09-28 Online:2019-12-28 Published:2019-12-23

摘要/Abstract

摘要： 骨硬化蛋白(sclerostin)是骨形成的负性调节因子,通过抑制Wnt/β-连环蛋白(β-catenin)信号通路,抑制成骨细胞的成骨作用。骨硬化蛋白抗体(sclerostin monoclonal antibody,Scl-Ab)则通过拮抗其对骨形成的负向调节作用而保证Wnt/β-catenin信号通路的正常传导。相比其他促骨形成的药物,Scl-Ab在促进新骨形成的同时,避免刺激破骨活动。目前已经研制出多种Scl-Ab,其中最具代表性的Romosozumab已经完成了临床Ⅲ期实验,证明其可以显著促进骨形成,降低骨吸收。但其临床疗效和安全性仍在探讨,还需进一步的长期研究。本文对Scl-Ab的临床研究进行综述,以期为相关实验研究和临床治疗提供理论基础。

关键词: 骨硬化蛋白抗体, Romosozumab, 骨再生

Abstract: Sclerostin is a negative regulator of bone formation and inhibits bone formation by inhibiting the Wnt/β-catenin signaling pathway. Sclerostin antibody (Scl-Ab) ensures the transmission of the Wnt/β-catenin signaling pathway by antagonizing the negative regulation of sclerostin on bone formation. Compared to other osteogenic drugs, Scl-Ab can stimulate osteogenic activity without stimulating osteoclast activity. A variety of Scl-Ab have been developed. Romosozumab, the most representative antibody, has completed clinical phase III trials, demonstrating that it can significantly promote bone formation and inhibit bone resorption. However, clinical efficacy and safety of Scl-Ab is still unclear and requires further investigation and discussion. Therefore, this review was conducted in order to provide theoretical basis for experimental research and clinical treatment.

Key words: sclerostin antibody, Romosozumab, bone regeneration

梁婷婷, 郭吕华. 骨硬化蛋白抗体的临床研究进展[J]. 口腔医学研究, 2019, 35(12): 1119-1121.

LIANG Tingting, GUO Lvhua. Research Progress on Sclerostin Antibody[J]. Journal of Oral Science Research, 2019, 35(12): 1119-1121.

参考文献

[1] Opar A. Late-stage osteoporosis drugs illustrate challenges in the field [J]. Nat Rev Drug Discov, 2009, 8(10): 757-758.
[2] Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis [J]. J Bone Miner Res, 2009, 24(4): 578-588.
[3] Yakar N, Guncu GN, Akman AC, et al. Evaluation of gingival crevicular fluid and peri-implant crevicular fluid levels of sclerostin, TWEAK, RANKL and OPG [J]. Cytokine, 2019, 113: 433-439.
[4] Jacobsen CM. Application of anti-Sclerostin therapy in non-osteoporosis disease models [J]. Bone, 2017, 96:18-23.
[5] Liu YS, Liu XB, Qiu YY, et al. Molecular mechanism of Wnt signal pathway in multiple myeloma cell line H929 cell autophagy [J]. Eur Rev Med Pharmacol Sci, 2018, 22(11):3327-3332.
[6] Choi J, Lee K, Kang M, et al. In silico discovery of quinoxaline derivatives as novel LRP5/6-sclerostin interaction inhibitors [J]. Bioorg Med Chem Lett, 2018, 28(6): 1116-1121.
[7] Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis [J]. N Engl J Med, 2016, 375(16): 1532-1543.
[8] Qin W, Li X, Peng Y, et al. Sclerostin antibody preserves the morphology and structure of osteocytes and blocks the severe skeletal deterioration after motor-complete spinal cord injury in rats [J]. J Bone Miner Res, 2016, 31(7):1482.
[9] Spatz JM, Ellman R, Cloutier AM, et al. Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading [J]. J Bone Miner Res, 2013, 28(4):865-874.
[10] Hay E, Bouaziz W, Funck-Brentano T, et al. Sclerostin and bone aging: a mini-review [J]. Gerontology, 2016, 62(6): 618-623.
[11] Herrero S, Pico Y. Treatments for post-menopausal osteoporotic women, what's new? How can we manage long-term treatment [J]. Eur J Pharmacol, 2016, 779: 8-21.
[12] Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody [J]. J Bone Miner Res, 2011, 26(1): 19-26.
[13] McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density [J]. N Engl J Med, 2014, 370(5): 412-420.
[14] Shah AD, Shoback D, Lewiecki EM. Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis [J]. Int J Womens Health, 2015, 7: 565-580.
[15] McColm J, Hu L, Womack T, et al. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women [J]. J Bone Miner Res, 2014, 29(4): 935-943.
[16] Recker RR, Benson CT, Matsumoto T, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density [J]. J Bone Miner Res, 2015, 30(2): 216-224.
[17] Recknor CP, Recker RR, Benson CT, et al. The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density [J]. J Bone Miner Res, 2015, 30(9): 1717-1725.
[18] Wang FS, Wu RW, Lain WS, et al. Sclerostin vaccination mitigates estrogen deficiency induction of bone mass loss and microstructure deterioration [J]. Bone, 2018, 112: 24-34.
[19] Yao Q, Ni J, Hou Y, et al. Expression of sclerostin scFv and the effect of sclerostin scFv on healing of osteoporotic femur fracture in rats [J]. Cell Biochem Biophys, 2014, 69(2): 229-235.
[20] 倪杰, 侯宇, 艾笛, 等. 骨硬化素单链抗体对去卵巢模型大鼠骨质疏松性骨折愈合的影响[J]. 中国药房, 2013, 24(45): 4240-4242.
[21] Florio M, Gunasekaran K, Stolina M, et al. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair [J]. Nat Commun, 2016, 7:11505.
[22] Napimoga MH, Nametala C, Da SF, et al. Involvement of the Wnt-beta-catenin signalling antagonists, sclerostin and dickkopf-related protein 1, in chronic periodontitis [J]. J Clin Periodontol, 2014, 41(6):550-557.
[23] Kuchler U, Schwarze UY, Dobsak T, et al. Dental and periodontal phenotype in sclerostin knockout mice [J]. Int J Oral Sci, 2014, 6(2):70-76.
[24] Lehnen SD, Gotz W, Baxmann M, et al. Immunohistochemical evidence for sclerostin during cementogenesis in mice [J]. Ann Anat, 2012,194(5): 415-421.
[25] Taut AD, Jin Q, Chung JH, et al. Sclerostin antibody stimulates bone regeneration after experimental periodontitis [J]. J Bone Miner Res, 2013, 28(11): 2347-2356.
[26] Han P, Ivanovski S, Crawford R, et al. Activation of the canonical Wnt signaling pathway induces cementum regeneration [J]. J Bone Miner Res, 2015, 30(7):1160-1174.

骨硬化蛋白抗体的临床研究进展

Research Progress on Sclerostin Antibody

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	程璐, 史剑杰. 骨膜减张技术在引导骨再生术中的应用研究进展[J]. 口腔医学研究, 2020, 36(9): 814-816.
[2]	乐柯, 董衡, 陈力, 杨光雯, 陈琳, 刘晖, 周娜, 牟永斌. 应用三维预成型钛网在上颌前牙区骨增量疗效的临床研究[J]. 口腔医学研究, 2020, 36(5): 481-485.
[3]	呙誉东, 周炼. 帐篷螺丝技术在上前牙区连续缺失种植修复中的疗效评价[J]. 口腔医学研究, 2020, 36(3): 298-301.
[4]	薛国平, 刘青梅. 低水平激光治疗应用于颌骨骨再生的研究进展[J]. 口腔医学研究, 2019, 35(9): 830-832.
[5]	陈瑞, 李风兰. 阿司匹林/富血小板纤维蛋白复合物促进大鼠种植体周围骨缺损修复的实验研究[J]. 口腔医学研究, 2019, 35(8): 761-765.
[6]	于文凤, 赵世俊, 吕敏敏, 崔凤林, 康梅珍, 张志媛. 浓缩生长因子在上颌前牙区引导骨再生术中的临床应用[J]. 口腔医学研究, 2019, 35(7): 676-680.
[7]	高筱萌,高海. 生物纳米材料在骨组织工程中的研究进展[J]. 口腔医学研究, 2019, 35(6): 524-526.
[8]	于婉琦, 杨诗卉, 周哲, 周延民, 赵静辉. 老年患者微创上颌窦底提升同期种植的临床研究[J]. 口腔医学研究, 2019, 35(3): 258-261.
[9]	郑钧元, 何俐, 胡图强, 王美钧. 铒激光治疗老年患者前磨牙牙周角型骨缺损的半年疗效观察1例[J]. 口腔医学研究, 2019, 35(3): 307-308.
[10]	季平, 杨生. 个性化钛网在口腔种植骨增量中的应用[J]. 口腔医学研究, 2019, 35(11): 1011-1015.
[11]	孙雨虹, 杨柳, 王硕, 夏露露, 郭瓅, 曹正国, 华先明. 牙周-正畸联合治疗上前牙重度牙周炎伴牙移位1例[J]. 口腔医学研究, 2019, 35(11): 1100-1102.
[12]	王超, 夏荣, 刘芮, 肖楠楠. 3D打印个性化钛网重建牙槽嵴骨缺损的实验研究[J]. 口腔医学研究, 2019, 35(1): 80-83.
[13]	朱艺丹, 何苗苗, 刘加涛, 刘艳云, 刘玉慧, 徐宁, 唐一月, 余占海. 载PTH-Fc/PLCL/SF静电纺丝屏障膜的构建与性能研究[J]. 口腔医学研究, 2018, 34(8): 913-918.
[14]	段子文, 马玉, 王冰杰, 阿孜古丽·阿扎提, 尼加提·吐尔逊. 牙周生物型对前牙区同期行GBR的种植修复美学效果的影响[J]. 口腔医学研究, 2018, 34(2): 176-180.
[15]	罗正文, 刘济远, 李佳, 潘剑. 引导组织再生生物膜应用于拔牙术后牙槽骨缺损修复的临床研究[J]. 口腔医学研究, 2017, 33(7): 782-786.